Evidence map›Paper›PMID 41996585›Full record

ArticleChembiochem : a European journal of chemical biology2026

Uracil-Peptide-Pyrene Conjugates as Cu

Dijana Pavlović Saftić, Lucija Lulić Horvat, Ivo Piantanida

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dijana Pavlović SaftićDivision of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Zagreb, Croatia.ORCID 0000-0002-0657-1635
Lucija Lulić HorvatDivision of Molecular Biology, Ruđer Bošković Institute, Zagreb, Croatia.
Ivo PiantanidaDivision of Organic Chemistry and Biochemistry, Ruđer Bošković Institute, Zagreb, Croatia.

Funding

Croatian Science Foundation HrZZ IP-2022-10-9829
6 · The paper itself

Abstract

We report a series of uracil-triazole-pyrene peptidomimetics (2-4) designed to achieve modular geometric control through peptide linkers of varying length and flexibility. All three compounds exhibited submicromolar affinity for ds-DNA, while compound 4 also showed strong binding to ds-RNA, demonstrating the advantage of combining a uracil recognition unit with an extended pyrene aromatic surface compared to the Pyr-Trp reference ligand and the phenanthridine analog 4'. Structural variations strongly affected Cu(II) coordination. Although Pyr-Trp bound Cu(II) approximately 1000-fold more strongly than the short, rigid compound 2, elongation and increased linker flexibility restored high affinity in 4. Notably, replacing phenanthridine (4') with pyrene (4) enhanced Cu(II) binding by nearly 100-fold, highlighting the superior coordination properties of the pyrene scaffold. Cu(II) complexation significantly enhanced nucleic acid binding exclusively for compound 2, increasing its DNA/RNA affinity 15-fold. The resulting 2-Cu(II) complex displayed exceptional selectivity for poly rA-poly rU, exceeding that of the Pyr-Trp-Cu(II) analog by more than 10-fold, consistent with uracil-mediated Hoogsteen-type recognition. Membrane interactions with POPC MLVs were linker-dependent, producing fluorescence enhancements of up to 1400% (2), 650% (3), and 100% (4). Together with negligible cytotoxicity, these findings indicate that compounds 2-4 represent promising multifunctional platforms for Cu

Indexed as

CopperDNAFluorescent DyesMembranes, ArtificialPeptidesPyrenesRNAUracilFluorescent Chemosensor CompoundsHumansCopperDNAFluorescent Chemosensor CompoundsFluorescent DyesMembranes, ArtificialPeptidespyrenePyrenesRNAUracil1,2,3‐triazole–uracil conjugatescopper(II) metal–ligand interactionsDNA/RNA fluorescent probespyrene‐based fluorophorestheranostic agents

Identifiers

PMID41996585
PMCPMC13089947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.